Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche

Bibliographic Details
Title: Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Authors: Antonio Giovanni Solimando, Eleonora Malerba, Patrizia Leone, Marcella Prete, Carolina Terragna, Michele Cavo, Vito Racanelli
Source: Frontiers in Oncology, Vol 12 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: multiple myeloma, drug resistance, bone marrow microenvironment, monoclonal gammopathy of undetermined significance, therapeutic targets, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Multiple myeloma (MM) is still an incurable disease, despite considerable improvements in treatment strategies, as resistance to most currently available agents is not uncommon. In this study, data on drug resistance in MM were analyzed and led to the following conclusions: resistance occurs via intrinsic and extrinsic mechanisms, including intraclonal heterogeneity, drug efflux pumps, alterations of drug targets, the inhibition of apoptosis, increased DNA repair and interactions with the bone marrow (BM) microenvironment, cell adhesion, and the release of soluble factors. Since MM involves the BM, interactions in the MM-BM microenvironment were examined as well, with a focus on the cross-talk between BM stromal cells (BMSCs), adipocytes, osteoclasts, osteoblasts, endothelial cells, and immune cells. Given the complex mechanisms that drive MM, next-generation treatment strategies that avoid drug resistance must target both the neoplastic clone and its non-malignant environment. Possible approaches based on recent evidence include: (i) proteasome and histone deacetylases inhibitors that not only target MM but also act on BMSCs and osteoclasts; (ii) novel peptide drug conjugates that target both the MM malignant clone and angiogenesis to unleash an effective anti-MM immune response. Finally, the role of cancer stem cells in MM is unknown but given their roles in the development of solid and hematological malignancies, cancer relapse, and drug resistance, their identification and description are of paramount importance for MM management.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.973836/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2022.973836
Access URL: https://doaj.org/article/e63e1f19b52240be80f01d26c41eae2b
Accession Number: edsdoj.63e1f19b52240be80f01d26c41eae2b
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2022.973836
Published in:Frontiers in Oncology
Language:English